Skip to main content
SpringerLink
Log in

Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Scleroderma (SSc) is a multisystem disorder characterized by fibrosis and collagen deposition in the dermis, but affects multiple organ systems, leading to esophageal dysmotility, renal failure, and interstitial lung disease (ILD). ILD is common manifestation of diffuse type of SSc and may be life threatening, and require aggressive therapy with cytotoxic agents. Although high-dose steroid and cyclophosphamide are most commonly used therapy for SSc-associated ILD, the efficacy is questionable in some cases and more effective and less toxic therapies are needed. Rituximab (RTX) is a chimeric mAb against human CD20 that depletes peripheral B cells and introduced for systemic rheumatic diseases. However, there were no enough evidences for SSc-associated ILD. We report herein a case of 47-year-old female with diffuse type of SSc with steroid and cyclophosphamide-resistant ILD that was successfully treated with RTX. Thus, we suggested that RTX could be an efficacious therapeutic modality for severe, conventional treatment-resistant SSc-associated ILD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666

    Article  PubMed  CAS  Google Scholar 

  2. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970

    Article  PubMed  CAS  Google Scholar 

  3. Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN, Andonopoulos AP (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27(4):357–361

    Article  PubMed  CAS  Google Scholar 

  4. Fujimoto M, Sato S (2005) B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 17(6):746–751

    Article  PubMed  Google Scholar 

  5. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF (2004) Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41(12):1123–1133

    Article  PubMed  CAS  Google Scholar 

  6. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169(3):954–966

    Article  PubMed  CAS  Google Scholar 

  7. Smith VP, Van Praet JT, Vandooren BR, Vander Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, de Keyser F (2008) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (epub ahead of print)

  8. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60(2):578–583

    Article  PubMed  Google Scholar 

  9. McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47(4):552–553

    Article  CAS  Google Scholar 

  10. Steen V (2004) Changes in causes of death in SSc over the past 30 years. Arthritis Rheum 50(S9)(Abstract 1052):S422

  11. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr (1985) Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 28(7):759–767

    Article  PubMed  CAS  Google Scholar 

  12. Maas D, Schramm A, Jackle B, Raif W, Schubothe H (1979) Progressive systemic sclerosis—long-term treatment with azathioprin (author’s transl). Immun Infekt 7(5):165–169

    PubMed  CAS  Google Scholar 

  13. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE (2006) Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 45(12):1572

    Article  CAS  Google Scholar 

  14. Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50(6):1918–1927

    Article  PubMed  Google Scholar 

  15. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100(21):12319–12324

    Article  PubMed  CAS  Google Scholar 

  16. Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56(9):3167–3168

    Article  PubMed  Google Scholar 

  17. Hasegawa M, Fujimoto M, Takehara K, Sato S (2005) Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 39(1):1–7

    Article  PubMed  CAS  Google Scholar 

  18. Bosello S, De Santis M, Lama G (2007) Clinical improvement in systemic slerosis patients treated with anti-CD20. Arthritis Rheum Sup 56:S494

    Google Scholar 

  19. Lombardi S, Quartuccio L, Franzolini N (2008) Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis. Arthritis Rheum Sup 58:S822–S823

    Google Scholar 

  20. Adams AB, Barillas-Arias L, Angeles ST, MacDermott EJ, Barinstein L, Lehman TJA (2006) Cyclophosphamide and rituximab combination therapy for the treatment of juvenile onset scleroderma: 6 Patient Case Series. In: Proceedings of ACR/ARHP annual scientific meeting 2006, Washington, DC, USA, pp 10–15

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, San 2-20 Geumam-dong, Deokjin-gu, Jeonju, Jeonbuk, 561-756, South Korea

    Wan-Hee Yoo

Authors
  1. Wan-Hee Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wan-Hee Yoo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoo, WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 32, 795–798 (2012). https://doi.org/10.1007/s00296-009-1347-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1347-z

Keywords

Search

Navigation